Increased Predictivity in Toxicity Testing
The assessment of new pharmaceuticals and chemicals is a complex process that incorporates information from in silico analyses, in vitro studies, and animal testing. Several recent events have led to an increased need for validated, physiologically relevant, and predictive human in vitro models:
- High attrition rate of new drugs in development
- Withdrawal of marketed drugs due to toxicity
- Increased focus on animal welfare issues due to legislative changes
- Biologically relevant human cell models
- Highly reproducible to ensure confidence in results
- Consistent availability to eliminate the need for repeat sourcing and validation
The importance of iCell and MyCell products to the future of safety assessment is best evidenced by a proposed new regulatory paradigm to validate and standardize the use of stem cell-derived cardiomyocytes in in vitro assays for predicting cardiac arrhythmia.
Browse the growing list of publications that demonstrate the use of iCell products for interrogating mechanisms of toxicity and improving predictivity.